Plain-English translation of NCT06747390 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing whether injecting lidocaine — a common numbing medication — directly into a throat tumor before surgery can help improve how well the body responds to cancer treatment. Researchers believe this injection might trigger an immune response that makes surgery more effective for people with HPV-related oropharyngeal cancer. Half of participants will receive the injection, and half will not, so doctors can compare the results.
Doctors want to find ways to help the immune system fight oropharyngeal cancer more effectively during surgery. This medication may work by triggering an immune response in the tumor itself, potentially improving outcomes for patients who choose surgery as their primary treatment.
You likely qualify if…
You likely don't qualify if…
You will come to the University of Pennsylvania for a procedure called direct laryngoscopy, during which doctors examine your throat under anesthesia and take a biopsy. At that same visit, you will randomly receive either a numbing injection directly into your tumor or no injection. Before and after this procedure, blood samples will be collected to study your immune response. After your study visit, you will receive your standard cancer treatment, which may include robotic surgery to remove the tumor and lymph nodes, radiation therapy, chemotherapy, or a combination of these — based on what your doctors recommend as best for your situation.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States